Related Experiment Video
Updated: May 23, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Biologics: the next generation of analgesic drugs?
Iain P Chessell1, Amanda Dudley, Andy Billinton
1MedImmune, Granta Park, Cambridge, UK. Chesselli@medimmune.com
Abstract:
For many decades, there have been few novel therapies for pain, and the number of promising targets that have been genuinely validated in the clinic is small. Discovery and development of biologic therapies for analgesia provides a better opportunity to test such targets, potentially providing new and effective therapies. Biologics have revolutionised the treatment of many diseases, with the greatest advances seen in oncology and inflammatory disorders. Across a broad spectrum of severe, chronic pain disorders - including inflammatory pain, neuropathic pain and cancer pain - biologics could offer patients safer and more-effective alternatives to currently available treatments. As such, progression of large-molecule therapies is becoming a strategic priority for companies as they look to advance their portfolios.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Opioid Analgesics: Morphine and Other Natural Cogeners

